Engineered strategies for enhancing mRNA vaccine stability in delivery and storage
Source abstract
Abstract
Messenger RNA (mRNA) vaccines, which leverage quick and customizable antigen production, have transformed immunization. However, their widespread use is still limited by challenges related to the natural instability of in vitro transcribed mRNA and the limitations of current delivery systems. Modern perspectives on stability extend beyond simple resistance to degradation. They now consider factors that can be modified through RNA structure and nanoscale environmental interactions. These interactions, which promote efficient translation, also affect the durability of these complexes against physical and chemical stresses. During formulation and storage, variables such as excipients, buffers, and solid-state architecture are essential for maintaining molecular integrity throughout manufacturing, transportation, and long-term preservation. As a result, stability serves as a key link between molecular design and overall vaccine efficacy, transforming a major obstacle into an area for strategic innovation. This review highlights recent advances at both the molecular and carrier levels aimed at developing thermostable, efficient, and highly effective mRNA vaccines, with a focus on improvements in their stability, storability, and delivery.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects · Protein purification and stability
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, China
State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, China
Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, China
Funding
National Natural Science Foundation of China · National Key Research and Development Program of China Stem Cell and Translational Research
References (100+)
Show source-provided references
1. Sahin · Nat. Rev. Drug Discovery · 2014 · 13 · 75910.1038/nrd4278 ↗
2. Pardi · Nat. Rev. Drug Discovery · 2018 · 17 · 26110.1038/nrd.2017.243 ↗
3. Ho · RSC Chem. Biol. · 2024 · 5 · 41810.1039/D4CB00022F ↗
4. Hou · Nat. Rev. Mater. · 2021 · 6 · 107810.1038/s41578-021-00358-0 ↗
5. Polack · N. Engl. J. Med. · 2020 · 383 · 260310.1056/NEJMoa2034577 ↗
6. Mata · npj Vaccines · 2025 · 10 · 13510.1038/s41541-025-01201-1 ↗
7. Xiong · Nano Res. · 2018 · 11 · 528110.1007/s12274-018-2146-1 ↗
8. Qin · Signal Transduction Targeted Ther. · 2022 · 7 · 16610.1038/s41392-022-01007-w ↗
9. Jones · J. Struct. Biol.: X · 2022 · 6 · 100066
10. Jin · J. Biol. Chem. · 2025 · 301 · 10801510.1016/j.jbc.2024.108015 ↗
11. Zhai · Nucleic Acid Insights · 2024 · 01 · 10110.18609/nai.2024.015 ↗
12. Liu · Front. Cell Dev. Biol. · 2022 · 10 · 90151010.3389/fcell.2022.901510 ↗
13. Muramatsu · Mol. Ther. · 2022 · 30 · 194110.1016/j.ymthe.2022.02.001 ↗
14. Schoenmaker · Int. J. Pharm. · 2021 · 601 · 12058610.1016/j.ijpharm.2021.120586 ↗
15. Leppek · Nat. Commun. · 2022 · 13 · 153610.1038/s41467-022-28776-w ↗
16. Guéguen · Eur. J. Pharm. Biopharm. · 2024 · 195 · 11407710.1016/j.ejpb.2023.08.002 ↗
17. Pontes · Biomater. Adv. · 2024 · 156 · 21371310.1016/j.bioadv.2023.213713 ↗
18. Henderson · Mol. Pharmaceutics · 2022 · 19 · 427510.1021/acs.molpharmaceut.2c00587 ↗
19. Ruppl · Int. J. Pharm. · 2025 · 671 · 12527210.1016/j.ijpharm.2025.125272 ↗
20. Yang · Adv. Healthc. Mater. · 2023 · 12 · 220268810.1002/adhm.202202688 ↗
21. Yadava · ACS Appl. Mater. Interfaces · 2024 · 16 · 1598110.1021/acsami.4c00992 ↗
22. Zeng · Curr. Top. Microbiol. Immunol. · 2022 · 440 · 71
23. Crommelin · J. Pharm. Sci. · 2021 · 110 · 99710.1016/j.xphs.2020.12.006 ↗
24. Ghaemmaghamian · Adv. Drug Delivery Rev. · 2022 · 187 · 11431310.1016/j.addr.2022.114313 ↗
25. Cao · Biomaterials · 2024 · 310 · 12262810.1016/j.biomaterials.2024.122628 ↗
26. Huang · Nat. Med. · 2022 · 28 · 227310.1038/s41591-022-02061-1 ↗
27. Gao · Acta Biomater. · 2021 · 131 · 110.1016/j.actbio.2021.06.020 ↗
28. Jung · Theranostics · 2022 · 12 · 750910.7150/thno.77259 ↗
29. Chatterjee · Proc. Natl. Acad. Sci. U. S. A. · 2024 · 121 · e230780012010.1073/pnas.2307800120 ↗
30. Li · Mol. Pharmaceutics · 2024 · 21 · 374310.1021/acs.molpharmaceut.4c00276 ↗
31. Chaudhary · Nat. Rev. Drug Discovery · 2021 · 20 · 81710.1038/s41573-021-00283-5 ↗
32. Tanaka · Adv. Drug Delivery Rev. · 2020 · 154–155 · 21010.1016/j.addr.2020.07.001 ↗
33. Paramasivam · J. Cell Biol. · 2022 · 221 · e20211013710.1083/jcb.202110137 ↗
34. Qiu · Research · 2023 · 6 · 014810.34133/research.0148 ↗
35. Shi · Chem. Mater. · 2024 · 36 · 542210.1021/acs.chemmater.4c00219 ↗
36. Blenke · J. Pharm. Sci. · 2023 · 112 · 38610.1016/j.xphs.2022.11.001 ↗
37. Zhang · J. Controlled Release · 2025 · 381 · 11355910.1016/j.jconrel.2025.02.055 ↗
38. Ai · Cell Discovery · 2023 · 9 · 910.1038/s41421-022-00517-9 ↗
39. Fahrni · J. Pharm. Policy Pract. · 2022 · 15 · 1610.1186/s40545-022-00411-5 ↗
40. Cheng · Nat. Commun. · 2025 · 16 · 470010.1038/s41467-025-60040-9 ↗
41. Uddin · Vaccines · 2021 · 9 · 103310.3390/vaccines9091033 ↗
42. Reinhart · Mol. Pharmaceutics · 2023 · 20 · 649210.1021/acs.molpharmaceut.3c00956 ↗
43. Liu · Nat. Biotechnol. · 2025 · 43 · 105810.1038/s41587-024-02424-8 ↗
44. Cerav · Plants · 2024 · 13 · 98210.3390/plants13070982 ↗
45. Kim · Mol. Cell. Toxicol. · 2022 · 18 · 110.1007/s13273-021-00171-4 ↗
46. Chen · Nat. Biotechnol. · 2025 · 43 · 112810.1038/s41587-024-02393-y ↗
47. Kim · Vaccine · 2024 · 42 · 183110.1016/j.vaccine.2023.07.024 ↗
48. Lu · J. Biomed. Sci. · 2024 · 31 · 8910.1186/s12929-024-01080-z ↗
49. Ren · J. Controlled Release · 2025 · 384 · 11394510.1016/j.jconrel.2025.113945 ↗
50. Lu · Pharm. Res. · 2025 · 42 · 106510.1007/s11095-025-03890-8 ↗
51. Paloncýová · J. Phys. Chem. Lett. · 2021 · 12 · 1119910.1021/acs.jpclett.1c03109 ↗
52. Zhang · Vaccines · 2023 · 11 · 158010.3390/vaccines11101580 ↗
53. Zhang · npj Vaccines · 2023 · 8 · 15610.1038/s41541-023-00751-6 ↗
54. Wang · Sci. Rep. · 2023 · 13 · 1674410.1038/s41598-023-43898-x ↗
55. Suk · Adv. Drug Delivery Rev. · 2016 · 99 · 2810.1016/j.addr.2015.09.012 ↗
56. Gao · ACS Nano · 2025 · 19 · 596610.1021/acsnano.4c09399 ↗
57. Zhang · J. Controlled Release · 2025 · 380 · 10810.1016/j.jconrel.2025.01.071 ↗
58. Kawaguchi · ACS Nano · 2025 · 19 · 2797710.1021/acsnano.5c10648 ↗
59. Albertsen · Adv. Drug Delivery Rev. · 2022 · 188 · 11441610.1016/j.addr.2022.114416 ↗
60. Haque · Int. J. Pharm.: X · 2024 · 8 · 100283
61. Tang · J. Nanobiotechnol. · 2025 · 23 · 22310.1186/s12951-025-03318-w ↗
62. Kafetzis · Adv. Healthcare Mater. · 2023 · 12 · 220302210.1002/adhm.202203022 ↗
63. Khan · Vaccines · 2025 · 13 · 85310.3390/vaccines13080853 ↗
64. Verhoef · Drug Delivery Transl. Res. · 2013 · 3 · 49910.1007/s13346-013-0176-5 ↗
65. Zelepukin · Nat. Commun. · 2024 · 15 · 436610.1038/s41467-024-48838-5 ↗
66. Vasileva · Front. Pharmacol. · 2024 · 15 · 146633710.3389/fphar.2024.1466337 ↗
67. Liu · Nat. Commun. · 2024 · 15 · 947110.1038/s41467-024-53914-x ↗
68. Chen · Proc. Natl. Acad. Sci. U. S. A. · 2022 · 119 · e220784111910.1073/pnas.2207841119 ↗
69. Borrajo · Drug Delivery Transl. Res. · 2024 · 14 · 204610.1007/s13346-024-01635-5 ↗
70. Z.Liu , et al. , Advancements in programmable lipid nanoparticles: Exploring the four-domain model for targeted drug delivery, arXiv , 2024, preprint, 10.48550/arXiv.2408.0569510.48550/arXiv.2408.05695 ↗
71. Yan · J. Controlled Release · 2022 · 342 · 24110.1016/j.jconrel.2022.01.008 ↗
72. Kowalski · Mol. Ther. · 2019 · 27 · 71010.1016/j.ymthe.2019.02.012 ↗
73. Zhang · Top. Curr. Chem. (Z) · 2017 · 375 · 2610.1007/s41061-017-0112-0 ↗
74. Zhang · Mol. Ther.–Nucleic Acids · 2023 · 32 · 56810.1016/j.omtn.2023.04.019 ↗
75. Xu · Polym. Sci. Technol. · 2025 · 1 · 17110.1021/polymscitech.5c00010 ↗
76. Mendes · Nat. Rev. Methods Primers · 2022 · 2 · 2410.1038/s43586-022-00104-y ↗
77. Xu · Macromol. Biosci. · 2024 · 24 · 230023810.1002/mabi.202300238 ↗
78. Ke · Carbohydr. Polym. · 2025 · 362 · 12369910.1016/j.carbpol.2025.123699 ↗
79. Preston · Adv. Drug Delivery Rev. · 2021 · 171 · 5010.1016/j.addr.2021.01.016 ↗
80. Jain · J. Funct. Biomater. · 2023 · 14 · 43710.3390/jfb14090437 ↗
81. Gao · Langmuir · 2025 · 41 · 300710.1021/acs.langmuir.4c04788 ↗
82. Zhang · J. Polym. Sci. · 2024 · 62 · 223110.1002/pol.20230916 ↗
83. Chehelgerdi · Mol. Cancer · 2023 · 22 · 16910.1186/s12943-023-01865-0 ↗
84. Eslami · Vaccines · 2025 · 13 · 58810.3390/vaccines13060588 ↗
85. Bouazzaoui · Vaccine: X · 2024 · 19 · 100500
86. DeLong · ACS Pharmacol. Transl. Sci. · 2024 · 7 · 70710.1021/acsptsci.3c00280 ↗
87. Liu · Langmuir · 2017 · 33 · 1447210.1021/acs.langmuir.7b03209 ↗
88. Boisguérin · Biomedicines · 2021 · 9 · 58310.3390/biomedicines9050583 ↗
89. Udhayakumar · Adv. Healthcare Mater. · 2017 · 6 · 160141210.1002/adhm.201601412 ↗
90. Sharma · Pharmaceutics · 2019 · 11 · 49310.3390/pharmaceutics11100493 ↗
91. Koh · Sci. Rep. · 2018 · 8 · 1184210.1038/s41598-018-30290-3 ↗
92. Straeten · Nat. Biotechnol. · 2024 · 42 · 51010.1038/s41587-023-01774-z ↗
93. Waghule · Biomed. Pharmacother. · 2019 · 109 · 124910.1016/j.biopha.2018.10.078 ↗
94. Aldawood · Polymers · 2021 · 13 · 281510.3390/polym13162815 ↗
95. Quan · J. Controlled Release · 2010 · 147 · 32610.1016/j.jconrel.2010.07.125 ↗
96. Mistilis · Drug Delivery Transl. Res. · 2017 · 7 · 19510.1007/s13346-016-0282-2 ↗
97. Arya · J. Controlled Release · 2016 · 240 · 13510.1016/j.jconrel.2015.11.019 ↗
98. Rouphael · Lancet · 2017 · 390 · 64910.1016/S0140-6736(17)30575-5 ↗
99. Vassilieva · Front. Immunol. · 2021 · 11 · 58325110.3389/fimmu.2020.583251 ↗
100. Qi · Molecules · 2023 · 28 · 741110.3390/molecules28217411 ↗